Atlas Trials

NS Pharma, Inc.

15 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch NS Pharma, Inc.

RecordFirmDate
Clinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (PAH) (NCT07441200)NS Pharma, Inc.2026-07-01
A Clinical Trial of NS-863 in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) (NCT07441278)NS Pharma, Inc.2026-07-01
NS-050/NCNP-03 in Boys With DMD (Meteor50) (NCT06053814)NS Pharma, Inc.2024-09-18
NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD) (NCT05996003)NS Pharma, Inc.2024-02-22
Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis (NCT06046222)NS Pharma, Inc.2023-12-20
Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis (NCT04854096)NS Pharma, Inc.2023-01-31
Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With DMD (Galactic53) (NCT04956289)NS Pharma, Inc.2021-07-01
Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502) (NCT04687020)NS Pharma, Inc.2021-06-10
Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X) (NCT04768062)NS Pharma, Inc.2021-04-13
Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53) (NCT04060199)NS Pharma, Inc.2020-04-14
Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD) (NCT03167255)NS Pharma, Inc.2017-07-06
Safety and Dose Finding Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD) (NCT02740972)NS Pharma, Inc.2016-12-01
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF (NCT01423851)NS Pharma, Inc.2011-06-01
Study of NS-9 in Patients With Liver Metastases (NCT00094003)NS Pharma, Inc.2002-09-01
The Expanded Access Use of Viltolarsen in Duchenne Muscular Dystrophy With Confirmed Exon 53 Amenable Mutation (NCT04337112)NS Pharma, Inc.

Track NS Pharma, Inc. automatically

Every clearance here is in the API, with alerts when new ones post.